Literature DB >> 21349265

Lafutidine, a unique histamine H2-receptor antagonist, inhibits distention-induced gastric acid secretion through an H2 receptor-independent mechanism.

Motoko Nakano1, Shizuo Kitano, Masato Nanri, Mamoru Kiniwa.   

Abstract

Gastric acid secretion during the daytime has been implicated in the pathogenesis of acid-related diseases. Although daytime acid secretion is mainly governed by the parasympathetic vagal nerve, clinical observations have been accumulated that the H(2)-receptor antagonist lafutidine may have a strong effect. Here, we examined the actions of H(2)-receptor antagonists in a rat model of gastric acid secretion induced by stomach distention, a major post-meal stimulus. Indeed, the acid output during a 3h period after the instillation of saline into pylorus-ligated SD rats under urethane anesthesia was dependent on the instilled volume and was strongly suppressed by a vagotomy or the intraduodenal administration of atropine. Interestingly, lafutidine, but not famotidine or cimetidine, administered at a sufficient dose to block histamine-dependent acid secretion was capable of inhibiting distention-induced acid secretion. Moreover, gastric acid secretion induced by the intravenous perfusion of carbachol into SD rats was strongly inhibited by lafutidine but only partially inhibited by famotidine. The antisecretory action of lafutidine under these conditions was partly reversed by the co-administration of the nitric oxide synthase inhibitor L-NMMA, but was hardly affected by denervation with capsaicin or by the administration of the transient receptor potential channel V1 (TRPV1) antagonist capsazepine. Together with the observation that lafutidine increased the amount of intragastric nitric oxide, the present results suggest that lafutidine inhibits daytime gastric acid secretion not only by blocking H(2) receptors, but also through nitric oxide-mediated and histamine-independent indirect actions.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21349265     DOI: 10.1016/j.ejphar.2011.02.007

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

Review 1.  Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease.

Authors:  Yu-Min Kung; Wen-Hung Hsu; Meng-Chieh Wu; Jiunn-Wei Wang; Chung-Jung Liu; Yu-Chung Su; Chao-Hung Kuo; Fu-Chen Kuo; Deng-Chyang Wu; Yao-Kuang Wang
Journal:  Dig Dis Sci       Date:  2017-11-06       Impact factor: 3.199

2.  Efficacy of Lafutidine Versus Famotidine in Patients with Reflux Esophagitis: A Multi-Center, Randomized, Double-Blind, Non-inferiority Phase III Trial.

Authors:  Eun Hye Kim; Yong Chan Lee; Young Woon Chang; Jong-Jae Park; Hoon Jai Chun; Hwoon-Yong Jung; Hyun-Soo Kim; Hyun Yong Jeong; Sang-Young Seol; Sok Won Han; Myung-Gyu Choi; Soo-Heon Park; Ok-Jae Lee; Jin Tae Jung; Dong Ho Lee; Hyun Chae Jung; Soo Teik Lee; Jae Gyu Kim; Sei Jin Youn; Hak Yang Kim; Sang Woo Lee
Journal:  Dig Dis Sci       Date:  2014-12-23       Impact factor: 3.199

3.  Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin.

Authors:  Takahiro Suzuki; Takuma Kagami; Takahiro Uotani; Mihoko Yamade; Yasushi Hamaya; Moriya Iwaizumi; Satoshi Osawa; Ken Sugimoto; Hiroaki Miyajima; Takahisa Furuta
Journal:  Eur J Clin Pharmacol       Date:  2017-10-06       Impact factor: 2.953

4.  Randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia.

Authors:  Somnath Maity; Supriyo Choudhury; Avijit Hazra; Amal Kanti Das
Journal:  Indian J Pharmacol       Date:  2014 Sep-Oct       Impact factor: 1.200

5.  Regioselective Pd-catalyzed α-alkylation of furans using alkyl iodides.

Authors:  Jiaqi Yuan; Xiaofei Zhang; Chunhao Yang
Journal:  RSC Adv       Date:  2021-04-14       Impact factor: 3.361

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.